Literature DB >> 8147962

Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic.

K M De Cock1, G Adjorlolo, E Ekpini, T Sibailly, J Kouadio, M Maran, K Brattegaard, K M Vetter, R Doorly, H D Gayle.   

Abstract

Although human immunodeficiency virus type 1 (HIV-1) and HIV-2 share modes of transmission, their epidemiologic characteristics differ and international spread of HIV-2 has been very limited. Recently, the prevalence of infection with HIV-1 but not HIV-2 has increased rapidly in different West African countries, where HIV-2 was probably present earlier. Among 19,701 women of reproductive age tested in Abidjan, Ivory Coast, between 1988 and 1992, the prevalence of HIV-1 infection increased from 5.0% to 9.2%, while that of HIV-2 declined from 2.6% to 1.5%. Differences in viral load may be responsible: reported results of virus culture and polymerase chain reaction assays suggest that at high CD4+ T-lymphocyte counts viral load is lower in HIV-2-infected than in HIV-1-infected persons; the efficacy of heterosexual and perinatal transmission of HIV-2 is less efficient than that of HIV-1 at this stage. At low (< 0.20 x 10(9)/L [< 200/microL]) CD4+ T-lymphocyte counts, virus isolation is equally successful for both viruses, and the efficacy of heterosexual transmission is similar. Differences in HIV-1 and HIV-2 natural history are reflected in differences in viral load, that for HIV-2 being lower until immunodeficiency is severe. Differences in viral load throughout most of the natural history of infection appear to correlate with lower transmissibility of HIV-2 than HIV-1, and are the likeliest explanation for their markedly different global epidemiology.

Entities:  

Mesh:

Year:  1993        PMID: 8147962     DOI: 10.1001/jama.270.17.2083

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  55 in total

1.  Tracing the origin and history of the HIV-2 epidemic.

Authors:  Philippe Lemey; Oliver G Pybus; Bin Wang; Nitin K Saksena; Marco Salemi; Anne-Mieke Vandamme
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-12       Impact factor: 11.205

2.  Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.

Authors:  Michel Ntemgwa; Bluma G Brenner; Maureen Oliveira; Daniela Moisi; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

3.  Highly sensitive method for amplification of human immunodeficiency virus type 2 DNA.

Authors:  F Damond; I Loussert-Ajaka; C Apetrei; D Descamps; S Souquière; A Leprêtre; S Matheron; F Brun-Vézinet; F Simon
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

4.  Changing HIV epidemics: what HIV-2 can teach us about ending HIV-1.

Authors:  Geoffrey S Gottlieb
Journal:  AIDS       Date:  2013-01-02       Impact factor: 4.177

5.  Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa.

Authors:  Geoffrey S Gottlieb; Ndeye Mery Dia Badiane; Stephen E Hawes; Louise Fortes; Macoumba Toure; Cheikh T Ndour; Alison K Starling; Fatou Traore; Fatima Sall; Kim G Wong; Stephen L Cherne; Donovan J Anderson; Stefanie A Dye; Robert A Smith; James I Mullins; Nancy B Kiviat; Papa Salif Sow
Journal:  Clin Infect Dis       Date:  2009-02-15       Impact factor: 9.079

6.  Virological Characterization of Dual HIV-1/HIV-2 Seropositivity and Infections in Southern Ghana.

Authors:  Kwc Sagoe; Jaa Mingle; Rk Affram; S Britton; A Dzokoto; A Sonnerborg
Journal:  Ghana Med J       Date:  2008-03

7.  Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry.

Authors:  S M Owen; D Ellenberger; M Rayfield; S Wiktor; P Michel; M H Grieco; F Gao; B H Hahn; R B Lal
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

8.  Detection of simian immunodeficiency virus in diverse species and of human immunodeficiency virus Type 2 by using consensus primers within the pol region.

Authors:  Silvina Masciotra; Chunfu Yang; Danuta Pieniazek; Chanda Thomas; Sherry M Owen; Harold M McClure; Renu B Lal
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

9.  Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain.

Authors:  G D Ritter; G Yamshchikov; S J Cohen; M J Mulligan
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

10.  Primary simian immunodeficiency virus SIVmnd-2 infection in mandrills (Mandrillus sphinx).

Authors:  Richard Onanga; Sandrine Souquière; Maria Makuwa; Augustin Mouinga-Ondeme; François Simon; Cristian Apetrei; Pierre Roques
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.